| 25.1866 -0.388 (-1.52%) | 11-17 16:00 | |||||||||||||
|
|
| Short term | ||||
| Mid term | |
|||
| Targets | 6-month : | 30.08 | 1-year : | 30.53 |
| Resists | First : | 25.75 | Second : | 26.13 |
| Pivot price | 25.72 |
|||
| Supports | First : | 25.12 | Second : | 20.9 |
| MAs | MA(5) : | 25.75 |
MA(20) : | 25.69 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.3 |
D(3) : | 66 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 26.13 | Low : | 24.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TMID ] has closed above bottom band by 6.8%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 25.58 - 25.74 | 25.74 - 25.85 |
| Low: | 24.8 - 25 | 25 - 25.15 |
| Close: | 24.92 - 25.22 | 25.22 - 25.42 |
T. Rowe Price Mid Cap Equity Research ETF is an actively managed exchange-traded fund that seeks long-term capital growth by investing primarily in U.S. mid-cap companies. The fund uses a research-driven approach to construct a portfolio with characteristics similar to the Russell Mid-Cap Index, while overweighting companies viewed favorably and underweighting or avoiding those viewed less favorably.
Mon, 16 Nov 2026
T. Rowe Price Mid-Cap Equity Research ETF (TMID) stock price, news, quote and history - Yahoo Finance Australia
Mon, 16 Nov 2026
T. Rowe Price Mid-Cap Equity Research ETF (TMID) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 13 Nov 2026
T. Rowe Price Mid-Cap Equity Research ETF (TMID) stock price, news, quote and history - Yahoo Finance UK
Sat, 26 Sep 2026
T. Rowe Price’s New Active Biotech and Small-Cap ETFs Might Change The Case For Investing In TROW - Yahoo Finance
Thu, 17 Sep 2026
TMID ETF Price and Chart — NASDAQ:TMID - TradingView
Thu, 17 Sep 2026
T. Rowe Price Launches Three Active ETFs Across Biotech and U.S. Equities - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |